Non Alcoholic Fatty Liver Disease Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Non Alcoholic Fatty Liver Disease stocks.

Non Alcoholic Fatty Liver Disease Stocks Recent News

Date Stock Title
Aug 1 GALT Galectin Therapeutics appoints Khurram Jamil as chief medical officer
Aug 1 GALT Galectin Therapeutics Appoints Khurram Jamil, M.D. to Chief Medical Officer
Aug 1 SGMT Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors
Jul 31 IVA Inventiva reports preliminary HI 2024 data
Jul 31 IVA Inventiva Reports Preliminary 2024 First-Half Financial Information¹
Jul 31 SGMT Sagimet Biosciences' Denifanstat Remains A Strong Buy Despite Eli Lilly's Tirzepatide
Jul 30 ALGS Aligos Therapeutics to Announce 2nd Quarter 2024 Financial Results on August 6, 2024
Jul 30 GALT Galectin Therapeutics Inc.'s (NASDAQ:GALT) largest shareholders are retail investors with 57% ownership, insiders own 20%
Jul 30 VKTX Better Weight Loss Drug Stock: Viking Therapeutics vs. Zealand Pharma
Jul 29 VKTX Wall Street is still jittery on GLP-1s
Jul 29 VKTX The Bull Case for Viking Therapeutics Just Got Even Stronger. Here's Why You Should Buy It.
Jul 29 ALGS Companies Like Aligos Therapeutics (NASDAQ:ALGS) Could Be Quite Risky
Jul 29 VKTX Weight Loss Drug Stocks Just Took a Hit. Should You Buy the Stock That Caused It?
Jul 29 VKTX Attention, Growth Investors: This Biotech Stock Is Crushing Nvidia.
Jul 28 VKTX ViaSat & AST SpaceMobile Are Among Top 6 Mid Cap Stocks That Shined The Brightest Last Week (July 21-July 27): Are The Others In Your Portfolio?
Jul 27 VKTX Is Viking Therapeutics a Millionaire-Maker Stock?
Jul 26 VKTX June PCE inflation print, auto earnings: Morning Brief
Jul 26 VKTX Viking’s new dual GLP-1R/GIPR agonist expected to start Phase III trials soon
Jul 26 VKTX Eli Lilly loses $120B in value over Viking's GLP-1 progress
Jul 26 GNFT GENFIT: Positive Opinion from EMA Committee for Ipsen’s Iqirvo® (elafibranor) in Primary Biliary Cholangitis
Non Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) is a condition in which fat builds up in the liver, causing inflammation and damage. It is the most common form of liver disease in the United States, affecting up to 25% of the population. NAFLD is closely linked to obesity, diabetes, and high cholesterol, and can lead to serious complications such as cirrhosis and liver cancer. Treatment typically involves lifestyle changes such as weight loss, exercise, and a healthy diet.

Browse All Tags